There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Silk Road Medical (SILK – Research Report) and Viemed Healthcare (VMD – Research Report) with bullish sentiments.
Silk Road Medical (SILK)
Lake Street analyst Frank Takkinen reiterated a Buy rating on Silk Road Medical today and set a price target of $28.00. The company’s shares closed last Tuesday at $17.43.
According to TipRanks.com, Takkinen is a 4-star analyst with an average return of
Currently, the analyst consensus on Silk Road Medical is a Moderate Buy with an average price target of $20.71.
See Insiders’ Hot Stocks on TipRanks >>
Viemed Healthcare (VMD)
Lake Street analyst Brooks O’Neil maintained a Buy rating on Viemed Healthcare today and set a price target of $15.00. The company’s shares closed last Tuesday at $8.84.
According to TipRanks.com, O’Neil is a 2-star analyst with an average return of
Currently, the analyst consensus on Viemed Healthcare is a Moderate Buy with an average price target of $15.38.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SILK:
- Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuroprotection System PLUS
- Argus upgrades Silk Road Medical to Buy amid expanding commercial footprint
- Silk Road Medical upgraded to Buy from Hold at Argus
- Silk Road Medical expands TCAR portfolio with launch of tapered ENROUTE system
- Silk Road Medical Expands TCAR® Portfolio with Launch of Tapered ENROUTE® Transcarotid Stent System
